The mitochondrial caseinolytic protease P (ClpP) plays a central role in mitochondrial protein
quality control by degrading misfolded proteins. Using genetic and chemical approaches, …

Drug target identification is a crucial step in development, yet is also among the most
complex. To address this, we develop BANDIT, a Bayesian machine-learning approach that …

ONC201 was originally discovered as TNF-Related Apoptosis Inducing Ligand (TRAIL)-inducing
compound TIC10. ONC201 appears to act as a selective antagonist of the G protein …

Background H3 K27M-mutant diffuse midline glioma is a fatal malignancy with no proven
medical therapies. The entity predominantly occurs in children and young adults. ONC201 is a …

Purpose: ONC201 is a small-molecule selective antagonist of the G protein–coupled
receptor DRD2 that is the founding member of the imipridone class of compounds. A first-in-human …

ONC201 is the founding member of a novel class of anti-cancer compounds called
imipridones that is currently in Phase II clinical trials in multiple advanced cancers. Since the …

Two open‐label studies assessed the effects of hepatic and renal impairment on anidulafungin
pharmacokinetics. A single 50‐mg dose was administered intravenously to subjects with …

Background ONC201 is a dopamine receptor D2 (DRD2) antagonist that penetrates the
blood–brain barrier. ONC201 efficacy has been shown in glioblastoma animal models and is …

Anidulafungin is a novel antifungal agent of the echinocandin class that is intended for the
treatment of invasive fungal disease. It is likely that anidulafungin will be coadministered with …

Anti-cancer small molecule ONC201 upregulates the integrated stress response (ISR) and
acts as a dual inactivator of Akt/ERK, leading to TRAIL gene activation. ONC201 is under …